- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00289341
Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.
A Phase I/II Study of Autologous Dendritic Cells Pulsed With Apoptotic Tumor Cells (DC/LNCaP) Administered Subcutaneously to Prostate Cancer Patients.
연구 개요
상세 설명
연구 유형
등록 (실제)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 장소
-
-
New York
-
New York, New York, 미국, 10021
- Rockefeller University Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Disease Characteristics
- Histologically confirmed prostate carcinoma
- Progressive, disease required, i.e.: elevated PSA documented to be rising on 3 occasions, either despite castrate testosterone levels (below 50 ng/dl), or after definitive local therapy (prostatectomy or radiation).
Prior/Concurrent Therapy
-Biologic therapy:
Recovered from toxicity of any prior therapy
-Chemotherapy:
- At least 4 weeks since chemotherapy -Endocrine evaluation/therapy
- 3 rising PSA values at least 2 weeks apart
- At least 2 weeks since concurrent corticosteroids (other than for replacement therapy for adrenal insufficiency)
Medical hormonal therapy to maintain castrate testosterone levels permitted
-Radiotherapy:
At least 4 weeks since radiotherapy
-Surgery:
- Prior surgery allowed
Patient Characteristics
- Age: 18 and over, able to give written informed consent. Individuals unable to provide informed consent must have consent provided by the legal guardian, or person designated by the subject to give consent on his behalf.
- Performance status: Karnofsky 70-100%
- Life expectancy: At least 1 year
- Hematopoietic: obtained twice, once within 45 days prior to study entry, and again within 72 hours of study entry.
- WBC greater than 3,800
- Absolute neutrophils greater than 1,500
- Absolute lymphocytes greater than 500
- Platelets greater than 120,000
- Hb at least 10 g/dl
Hepatic:
--Bilirubin less than 2.0 mg/dl OR
--SGOT less than 2 x ULN
Renal:
- Creatinine no greater than 2.0 mg/dl OR
- Creatinine clearance at least 40 ml/min
Rheumatologic:
--ANA no greater than upper limit of normal, or ANA abnormal in absence of clinical signs of autoimmunity.
- Rheumatoid factor (RF) no greater than upper limit of normal, or RF abnormal in absence of clinical signs of autoimmunity.
- Anti-ds DNA no greater than upper limit of normal, or anti ds DNA abnormal in absence of clinical signs of autoimmunity.
- Immunologic:
- Influenza serology (assessment made at time of screening).
- Assessment of DTH response to a standard anergy panel (to include candida, trichophyton and tetanus) or to a Multitest CMI (a disposable kit for DTH testing with standardized preloaded antigens).
Endocrine:
--TSH, T3, and T4 no greater than upper limit of normal
Radiographic:
- Baseline bone scan
- Baseline CT or MRI of abdomen and pelvis
Exclusion Criteria:
Disease Characteristics -No active CNS metastases
Prior/Concurrent Therapy
Biologic therapy:
- No prior autologous or allogeneic tumor vaccines
- No concurrent other immunotherapy
Chemotherapy
--Not previously treated with more than 2 chemotherapy regimens
- No concurrent chemotherapy
- Radiotherapy --No concurrent radiotherapy
Patient Characteristics -Cardiovascular: No NYHA class III/IV status No active angina, clinically significant cardiac arrythmia, recent (6 months) myocardial infarction
Pulmonary:
--No severe debilitating pulmonary disease
Other:
- No active infection requiring antibiotics
- No active pain requiring chronic opioid analgesics.
- Not HIV, hepatitis B or hepatitis C virus positive; anti-HIV, HbsAg and Hep C antibody negative
- No history of hypersensitivity to vaccine components
- No serious uncontrolled medical illness
- No currently active second malignancy other than non-melanoma skin cancer (note: a patient is NOT considered to have currently active malignancy if they have completed therapy and are now considered by their physician to be at less than 30% risk for relapse)
- No history of total lymph node irradiation
- No history of vasculitis, including but not limited to systemic necrotizing vasculitides (polyarteritis nodosa group), hypersensitivity vasculitis, Wegener's granulomatosis.
- No history of autoimmune disease.
- No use of hydroxyurea within 45 days of study entry
- No receipt of immune modulators or suppressors within 30 days prior to study entry, including but not limited to interferons and thalidomide. No active requirement for corticosteroids; prior use is acceptable.
- No psychiatric illness or social condition that, in the opinion of the investigator, would interfere with adherence to study requirements.
- No alcohol or drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
위약 비교기: Placebo
12 patients in the placebo Arm for 8 weeks followed by DC/LNCAP, DC/LNCaP-M1 and DC/KLH immunizations over 8 weeks.
|
Subcutaneous injection of vaccine vehicle only (5% DMSO in normal saline), followed by cross-over to Arm 1 design.
|
실험적: DC/LNCaP
12 patients, receiving DC/LNCaP, DC/LNCaP-M1 and DC/KLH immunizations over 8 weeks
|
Subcutaneous injection of DC/LNCaP, DC/LNCaP-M1, DC/KLH
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Adverse Event
기간: End of blinded phase (wk 9)
|
Occurrence of adverse events (AE) was compared between the placebo and vaccine groups during the blinded phase (the 1st 9 weeks).
At the end of this phase, all were unblinded, and those who received placebo crossed over to now receive vaccine.
All serious AEs and any other AEs that occurred 5 times or more are reported.
The exact binomial test was used to compare the occurrence of each AE between groups.
|
End of blinded phase (wk 9)
|
Immunogenicity of the DC/LNCaP Vaccine. Pre- vs Post-vaccination Bulk T Cell Proliferation (3H Thymidine Incorporation) by Type of Antigen. The "Number" Indicated is the Median Difference of Post-Pre, of Each Antigen Group.
기간: pre- vs post-vaccination. Pre-vaccination T cells were collected at Wk 0 and post-vaccination T cells were collected at Wk 13
|
The difference between post minus pre-vaccination bulk T cell proliferation was calculated for each antigen.
|
pre- vs post-vaccination. Pre-vaccination T cells were collected at Wk 0 and post-vaccination T cells were collected at Wk 13
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Change in PSA Slope, Pre- vs Post-vaccination.
기간: pre- vs post- vaccination PSA slopes.
|
To model the evolution of PSA (in log-scale) during the three study phases (pre-vaccine, vaccine, and post-vaccine phases), a mixed linear spline model was used.
Two knots (one at the start of the vaccine phase and the other at the start of the post-vaccine phase) were used to directly quantify the differences in slopes between each phase.
To account for the heterogeneous treatment effect and the repeated measures structure, random effects are incorporated into the model.
For the general model, random effects for the intercept, slope and the first knot were considered.
|
pre- vs post- vaccination PSA slopes.
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Robert B. Darnell, MD, PHD, Rockefeller University
간행물 및 유용한 링크
일반 간행물
- Frank MO, Kaufman J, Parveen S, Blachere NE, Orange DE, Darnell RB. Dendritic cell vaccines containing lymphocytes produce improved immunogenicity in patients with cancer. J Transl Med. 2014 Dec 5;12:338. doi: 10.1186/s12967-014-0338-3.
- Frank MO, Kaufman J, Tian S, Suarez-Farinas M, Parveen S, Blachere NE, Morris MJ, Slovin S, Scher HI, Albert ML, Darnell RB. Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer. PLoS One. 2010 Sep 1;5(9):e12367. doi: 10.1371/journal.pone.0012367.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
전립선암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)모병피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Weill Medical College of Cornell UniversityMillennium Pharmaceuticals, Inc.완전한신경내분비성 전립선암 | 소세포 전립선암 | Prostate Adenocarcinoma Plus > 신경내분비 표지자에 대한 50% 면역조직화학적 염색미국
-
Jonsson Comprehensive Cancer Center아직 모집하지 않음전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Rashmi Verma, MDNational Cancer Institute (NCI)모병거세저항성 전립선암 | 전이성 전립선 선암종 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.종료됨2기 전립선암 AJCC v8 | IIIA기 전립선암 AJCC v8 | IIIB기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | 3기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Assiut University아직 모집하지 않음South Egypt Cancer Institute(SECI)에서 소아 악성종양 환자에 대한 KDIGO 기준을 사용하여 AKI의 누적 발병률을 확인하기 위해
vaccine vehicle only에 대한 임상 시험
-
Beth Israel Deaconess Medical CenterNational Institute on Aging (NIA); Hebrew SeniorLife모병
-
Johns Hopkins UniversityMerck Sharp & Dohme LLC완전한
-
Northwell HealthNational Institute on Alcohol Abuse and Alcoholism (NIAAA)완전한
-
The Second Affiliated Hospital of Chongqing Medical...모병